Table 1.
Demographic and baseline cancer characteristics
| Characteristic | Total (n=55)* |
Symptomatic (n=28) |
Asymptomatic (n=24) |
PŦ |
|---|---|---|---|---|
| Age, years | 60.3 (44-76) | 59.8 (44-76) | 61.5 (45-76) | 0.52 |
|
| ||||
| Race | 0.06 | |||
| White | 48 (87.3) | 22 (78.6) | 23 (95.8) | |
| Asian | 4 (7.3) | 4 (14.3) | 0 | |
| African American | 1 (1.8) | 0 | 1 (4.2) | |
| Other | 2 (3.6) | 2 (7.1) | 0 | |
|
| ||||
| Hispanic | 4 (7.3) | 3 (10.7) | 1 (4.2) | 0.61 |
|
| ||||
| BMI | 0.40 | |||
| ≤25 | 28 (50.9) | 12 (42.9) | 14 (58.3) | |
| ≥26 | 27 (49.1) | 16 (57.1) | 10 (41.7) | |
|
| ||||
| Education | 0.72 | |||
| < HS Graduate | 2 (3.6) | 1 (3.4) | 1 (4.2) | |
| HS Graduate | 12 (21.8) | 5 (17.8) | 7 (29.2) | |
| College graduate | 20 (36.6) | 11 (39.4) | 8 (33.3) | |
| Graduate degree | 21 (38.2) | 11 (39.4) | 8 (33.3) | |
|
| ||||
| Drug | 1.00 | |||
| Anastrazole | 49 (89.1) | 26 (92.9) | 22 (91.7) | |
| Letrozole | 4 (7.3) | 2 (7.1) | 2 (8.3) | |
| Exemestane | 0 | 0 | 0 | |
|
| ||||
| Previous Tamoxifen | 20 (36.4) | 10 (35.7) | 9 (37.5) | 1.00 |
|
| ||||
| Cancer Stage | 0.04 | |||
| 1 | 34 (61.8) | 13 (46.3) | 19 (79.1) | |
| 2 | 17 (30.9) | 12 (42.9) | 4 (16.7) | |
| 3 | 4 (7.3) | 3 (10.7) | 1 (4.2) | |
|
| ||||
| Her2/Neu Positive | 7 (12.7) | 4 (14.3) | 3 (12.5) | 1.00 |
|
| ||||
| Surgery | 0.39 | |||
| Lumpectomy | 35 (63.5) | 16 (57.1) | 17 (70.9) | |
| Mastectomy | 20 (36.4) | 12 (42.9) | 7 (29.1) | |
|
| ||||
| Lymph Node DissectionΨ – no. (%) | 20 (36.6) | 13 (46.4) | 6 (25) | 0.15 |
|
| ||||
| Chemotherapy | 0.17 | |||
| Any | 24 (43.6) | 15 (53.6) | 8 (33.3) | |
| Taxol based | 15 (27.3) | 10 (35.7) | 4 (16.7) | |
|
| ||||
| Radiation | 39 (70.9) | 19 (67.9) | 18 (75) | 0.76 |
*
55 patients enrolled; 2 did not start AI and 1 lost to follow up. 52 patients were analyzed at 6 months (28 symptomatic and 24 asymptomatic).
Ŧ
p-value is comparing the symptomatic to asymptomatic
Ψ
Lymph node dissection was defined as ≥ 5 lymph nodes removed